eligibility_summary
Inclusion: ECOG 0-1, stage IV uveal melanoma or stage IV cutaneous melanoma progressed after >=1 prior line incl PD-1 +/- CTLA-4, if BRAF V600+, prior BRAF +/- MEK, measurable liver-dominant disease with >=1 resectable liver lesion. Life expectancy <3 mo, renal/hepatic dysfunction, cirrhosis/portal HTN, cytopenias, live vaccines, HIV/HBV/HCV, active autoimmune disease, steroids/immunosuppression, other anticancer/investigational tx, other active cancer, conditions limiting participation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Phase 1, single-arm study in liver-dominant metastatic uveal/cutaneous melanoma testing: 1) Autologous tumor-infiltrating lymphocytes (TIL) cell therapy via hepatic arterial infusion—ex vivo–expanded patient T cells that recognize tumor neoantigens via TCRs, kill melanoma cells through perforin/granzyme and cytokine release. 2) Melphalan via percutaneous hepatic perfusion—alkylating chemotherapy that DNA–crosslinks, used regionally for hepatic lymphodepletion/tumor debulking to enhance TIL engraftment. 3) Low-dose subcutaneous interleukin-2—cytokine therapy that activates IL-2R signaling to support T-cell proliferation, survival, and function. Targets: intrahepatic melanoma metastases, tumor-reactive CD8+/CD4+ T cells, IL-2 signaling pathway, and reduction of suppressive intrahepatic immune populations via chemo-conditioning.